title: Interleukin-6 and C-reactive protein levels after 3 years of treatment with darunavir/ritonavir monotherapy or darunavir/ritonavir + two nucleoside reverse transcriptase inhibitors in the MONET trial.
authors.forename: Jose
authors.initials: J
authors.lastname: Arribas
authors.forename: Andrew
authors.initials: A
authors.lastname: Hill
authors.forename: Ning
authors.initials: N
authors.lastname: Xi
authors.forename: Yvon
authors.initials: Y
authors.lastname: van Delft
authors.forename: Christiane
authors.initials: C
authors.lastname: Moecklinghoff
mesh_terms: D000328:Adult; D019380:Anti-HIV Agents / Q000008:administration & dosage*; D023241:Antiretroviral Therapy, Highly Active / Q000379:methods*; D015415:Biomarkers / Q000097:blood; D002097:C-Reactive Protein / Q000032:analysis*; D000069454:Darunavir; D005260:Female; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D006526:Hepatitis C / Q000150:complications / Q000473:pathology; D006801:Humans; D015850:Interleukin-6 / Q000097:blood*; D008297:Male; D019438:Ritonavir / Q000008:administration & dosage*; D013449:Sulfonamides / Q000008:administration & dosage*; D013997:Time Factors
chemical_list: D019380:Anti-HIV Agents; D015415:Biomarkers; D015850:Interleukin-6; D013449:Sulfonamides; D002097:C-Reactive Protein; D019438:Ritonavir; D000069454:Darunavir